Free Trial

hVIVO (LON:HVO) Trading Up 7.4% - What's Next?

hVIVO logo with Medical background

hVIVO plc (LON:HVO - Get Free Report)'s stock price was up 7.4% during trading on Friday . The company traded as high as GBX 15.75 ($0.20) and last traded at GBX 15.30 ($0.20). Approximately 2,298,550 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 3,292,127 shares. The stock had previously closed at GBX 14.25 ($0.18).

hVIVO Price Performance

The company has a market cap of £103.31 million, a PE ratio of 6.02 and a beta of 0.97. The stock has a fifty day simple moving average of GBX 16.40 and a two-hundred day simple moving average of GBX 21.08. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86.

Insider Buying and Selling

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total transaction of £520,581.82 ($665,195.27). 14.03% of the stock is currently owned by corporate insiders.

About hVIVO

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

Read More

Should You Invest $1,000 in hVIVO Right Now?

Before you consider hVIVO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.

While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market
5 Stocks to BUY Now as Tariff Uncertainty Fades

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines